CBS and metabolic disease: Sympathetic activity3 and peripheral chemosensitivity17 have been shown to be increased while GLP-1 signaling is altered in T2D.50 Thus, the GLP1-CBs pathway may serve as a novel therapeutic target for controlling sympathetic activity in metabolic disease states as well as hypertension.